Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BigKahuna, BooDog, KarinCA, noretreat, TOB, starbuxsux
Search This Board:
Last Post: 11/28/2014 3:59:03 AM - Followers: 508 - Board type: Free - Posts Today: 5

Cellceutix Corporation (CTIX) 
 

 

http://cellceutix.com/
 

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
CIK:  0001355250
 
Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.

 

Management:   http://cellceutix.com/team/
The above link is kept updated.

 
Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/
 

 
Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/
 
SEC Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:
EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 
 


 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
Wiki
CTIX News: Notice of Effectiveness (effect) 11/19/2014 06:01:25 AM
CTIX News: Securities Registration Statement (simplified Form) (s-3/a) 11/10/2014 05:31:51 PM
CTIX News: Securities Registration Statement (simplified Form) (s-3) 10/30/2014 04:31:15 PM
CTIX News: Current Report Filing (8-k) 10/24/2014 06:04:28 AM
CTIX News: ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK 10/14/2014 06:00:00 AM
PostSubject
#79657  Sticky Note Anonymous survey concerning listing status, pinks Vs. OTCQB. BooDog 11/25/14 01:28:44 PM
#77645  Sticky Note Cellceutix Makes Breakthrough in Cancer Research by Activating BigKahuna 11/11/14 08:36:44 AM
#74575  Sticky Note Cellceutix Announces Positive Top-Line Data From Phase 2b TOB 10/23/14 11:59:10 AM
#67831  Sticky Note $CTIX News, SEC filings, FDA trials, misc., and KarinCA 09/03/14 06:13:02 PM
#57289  Sticky Note Cellceutix Initiates Clinical Trial of Prurisol as New starbuxsux 03/25/14 09:02:21 AM
#79851   I prefer to believe in what Dr Menon NanoEngineer 11/28/14 03:59:03 AM
#79850   I agree with you and BK except that NanoEngineer 11/28/14 03:57:33 AM
#79849   BK,... very good point,... that should solve the cabel 11/28/14 01:21:25 AM
#79848   So to clarify this and to make sure Swish22 11/28/14 01:18:40 AM
#79847   To see the unreliability of HED, we only BigKahuna 11/28/14 12:01:56 AM
#79846   Can I use my bitcoins? etradeedge 11/27/14 09:33:26 PM
#79845   I have to clarify my earlier post: If frrol 11/27/14 09:27:15 PM
#79844   We don't need no stinkin' institutions. I think TheDane 11/27/14 09:22:29 PM
#79843   Yes, but patience, which none of us have etradeedge 11/27/14 06:46:27 PM
#79842   You're referring to Puma Biotech? The company has lousy engineer 11/27/14 06:32:06 PM
#79841   I do not believe that Kevetrin will show georgejjl 11/27/14 06:18:28 PM
#79840   Old but interesting reading: georgejjl 11/27/14 06:09:58 PM
#79839   That is where you are still wrong. georgejjl 11/27/14 06:08:29 PM
#79838   Great but you are still missing some significant NanoEngineer 11/27/14 05:58:03 PM
#79837   With that being said, it should be quite georgejjl 11/27/14 05:31:47 PM
#79836   What 2 P2 (lung and breast) cancer trials etradeedge 11/27/14 05:26:31 PM
#79835   Strictly speaking my math was correct. The conversion georgejjl 11/27/14 05:00:18 PM
#79834   Sticky the first three words of your post georgejjl BaartP 11/27/14 04:15:54 PM
#79833   By admitting BK's math is correct you are sox040713 11/27/14 03:50:18 PM
#79830   BigK is correct the 350mg/sq m for the georgejjl 11/27/14 02:05:13 PM
#79829   Divided not devided. There's examples on how to Apparition 11/27/14 12:28:08 PM
#79828   G what is your agenda and beef with K? tombrady12nh 11/27/14 12:19:38 PM
#79827   will do...got my calculator out and will verify...I hope! Smooth 11/27/14 12:12:46 PM
#79826   He's missing a step. Chazz123 11/27/14 12:06:44 PM
#79825   Is his math wrong? Have we got a Smooth 11/27/14 11:53:15 AM
#79824   Late 2013 summary reading of Cellceutix compounds for this: djs7 11/27/14 10:37:46 AM
#79823   Maybe that's it. I thought perhaps DOE had frrol 11/27/14 10:35:08 AM
#79822   So it is only in the later cohorts frrol 11/27/14 10:33:13 AM
#79821   Frrol, I think DOE is interested because energy Ultimate01 11/27/14 10:15:01 AM
#79820   I share your warm thoughts but we shouldn't Ultimate01 11/27/14 10:03:59 AM
#79819   Woo hoo!!! Ultimate01 11/27/14 09:47:31 AM
#79818   In regards to patient X shenanigan 11/27/14 09:23:24 AM
#79817   Not necessarily. The company's strategy is to get frrol 11/27/14 08:55:08 AM
#79816   Yes I noticed that too. Micro stock blogs frrol 11/27/14 08:46:01 AM
#79815   I thought it was the English! 1400 11/27/14 08:34:02 AM
#79814   Thanks sox. That is what I have govorchin 11/27/14 08:16:26 AM
#79813   Multiple myeloma is Kevetrin's best target as a georgejjl 11/27/14 05:27:23 AM
#79812   HAPPY THANKSGIVING DAY georgejjl 11/27/14 05:05:22 AM
#79811   Georges, I am afraid you're dead wrong. NanoEngineer 11/27/14 04:22:07 AM
#79810   Surely if that scenario eventuates where would that carpetdude 11/27/14 03:57:37 AM
#79809   Correct. 5 trials with 3 under fast track BigKahuna 11/27/14 03:50:30 AM
#79808   Yup, my guess would be pancreatic and ovarian sox040713 11/27/14 02:10:09 AM
#79807   Hopefully yet another compound added to CTIX's vast vip1999 11/27/14 01:58:16 AM
#79806   I'd forgotten retinoblastoma. They would still need to BigKahuna 11/27/14 01:38:34 AM
#79805   I made a mistake in my post the biodoc 11/27/14 01:33:31 AM
#79804   This is not a surprise (apart from the lousy engineer 11/27/14 01:03:22 AM
#79803   The planned Phase 2/3 trials are Leo’s way sox040713 11/27/14 12:26:24 AM
#79802   Chazz, appreciate your comments. I am not doing sox040713 11/27/14 12:06:38 AM
#79801   I don't think up-listing will make "taking over" thefamilyman 11/27/14 12:00:40 AM
#79800   Sox not telling you what to do but Chazz123 11/26/14 11:49:28 PM
PostSubject